Company research
AMICUS THERAPEUTICS, INC.
CIK 1178879Updated Nov 16, 2026
Historical securities (1)
FOLD · NASDAQ · equity · closed Apr 27, 2026FOLD price & chart
This listing closed Apr 27, 2026. Live provider charts are shown only for current listings.
About the company
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. To learn more, please visit the company’s website at www.amicusrx.com.
In the news
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--EKSO, FOLD, CWAN, and JHG News provided by Monteverde & Associates PC Jan 07, 2026, 13:40 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 7, 2026 /PRNewswire/ -- Class Action Attorney Juan Monte ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q2 2023 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 868,811,000Source | 786,557,000Source | 764,084,000Source | 815,303,000Source | 749,484,000Source | 730,093,000Source | 789,839,000Source | 721,789,000Source | 949,870,000Source | 785,033,000Source | 777,880,000Source | 724,167,000Source |
| Property, Plant and Equipment, NetUSD | 27,759,000Source | 30,438,000Source | 31,072,000Source | 28,570,000Source | 31,161,000Source | 30,238,000Source | 28,718,000Source | 32,421,000Source | 27,108,000Source | 29,383,000Source | 31,667,000Source | 30,778,000Source |
| GoodwillUSD | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 14,743,000Source | 18,026,000Source | 21,318,000Source | 15,570,000Source | 18,853,000Source | 22,145,000Source | 16,389,000Source | 19,672,000Source | 13,915,000Source | 17,198,000Source | 20,490,000Source | 23,000,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 190,553,000Source | 233,647,000Source | 263,320,000Source | 158,702,000Source | 209,335,000Source | 211,307,000Source | 181,657,000Source | 209,761,000Source | 214,010,000Source | 213,752,000Source | 246,994,000Source | 148,813,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 113,838,000Source | 98,073,000Source | 73,331,000Source | 105,849,000Source | 85,174,000Source | 63,716,000Source | 88,323,000Source | 76,433,000Source | 115,307,000Source | 101,099,000Source | 87,632,000Source | 66,196,000Source |
| Inventory, NetUSD | 177,928,000Source | 115,338,000Source | 56,936,000Source | 154,875,000Source | 81,320,000Source | 51,381,000Source | 132,412,000Source | 60,759,000Source | 228,819,000Source | 118,782,000Source | 59,696,000Source | 23,816,000Source |
| Assets, CurrentUSD | 594,066,000Source | 498,474,000Source | 463,256,000Source | 538,007,000Source | 461,701,000Source | 432,822,000Source | 510,799,000Source | 431,239,000Source | 676,173,000Source | 504,736,000Source | 483,061,000Source | 423,816,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 38,457,000Source | 35,306,000Source | 52,689,000Source | 46,285,000Source | 35,145,000Source | 52,099,000Source | 39,491,000Source | 54,444,000Source | 38,511,000Source | 34,909,000Source | 49,533,000Source | 40,209,000Source |
| Operating Lease, Right-of-Use AssetUSD | 21,549,000Source | 23,144,000Source | 29,511,000Source | 21,988,000Source | 22,611,000Source | 28,042,000Source | 22,138,000Source | 23,003,000Source | 21,138,000Source | 22,278,000Source | 26,312,000Source | 29,534,000Source |
| Other Assets, NoncurrentUSD | 12,897,000Source | 18,678,000Source | 21,130,000Source | 13,371,000Source | 17,361,000Source | 19,049,000Source | 13,998,000Source | 17,657,000Source | 13,739,000Source | 13,641,000Source | 18,553,000Source | 19,242,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 638,387,000Source | 607,732,000Source | 630,847,000Source | 610,999,000Source | 616,961,000Source | 618,512,000Source | 596,281,000Source | 591,095,000Source | 675,629,000Source | 590,988,000Source | 617,706,000Source | 601,120,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,017,000Source | 2,942,000Source | 2,890,000Source | 3,016,000Source | 2,923,000Source | 2,856,000Source | 3,016,000Source | 2,922,000Source | 3,037,000Source | 2,944,000Source | 2,918,000Source | 2,815,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,768,980,000Source | -2,754,919,000Source | -2,650,231,000Source | -2,786,286,000Source | -2,748,190,000Source | -2,628,654,000Source | -2,761,866,000Source | -2,732,493,000Source | -2,767,290,000Source | -2,740,180,000Source | -2,684,074,000Source | -2,532,490,000Source |
| Stockholders' Equity Attributable to ParentUSD | 230,424,000Source | 178,825,000Source | 133,237,000Source | 204,304,000Source | 132,523,000Source | 111,581,000Source | 193,558,000Source | 130,694,000Source | 274,241,000Source | 194,045,000Source | 160,174,000Source | 123,047,000Source |
| Additional Paid in Capital, Common StockUSD | 2,973,625,000Source | 2,905,760,000Source | 2,787,275,000Source | 2,956,839,000Source | 2,868,925,000Source | 2,733,148,000Source | 2,939,673,000Source | 2,853,550,000Source | 3,014,456,000Source | 2,926,115,000Source | 2,836,018,000Source | 2,664,744,000Source |
| Liabilities and EquityUSD | 868,811,000Source | 786,557,000Source | 764,084,000Source | 815,303,000Source | 749,484,000Source | 730,093,000Source | 789,839,000Source | 721,789,000Source | 949,870,000Source | 785,033,000Source | 777,880,000Source | 724,167,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 198,930,000Source | 158,138,000Source | 169,454,000Source | 167,647,000Source | 168,066,000Source | 159,235,000Source | 152,890,000Source | 142,102,000Source | 237,828,000Source | 148,702,000Source | 167,689,000Source | 139,018,000Source |
| Operating Lease, Liability, CurrentUSD | 8,662,000Source | 8,541,000Source | 7,765,000Source | 8,610,000Source | 8,112,000Source | 7,840,000Source | 8,562,000Source | 8,270,000Source | 8,741,000Source | 8,455,000Source | 8,324,000Source | 8,552,000Source |
| Accounts Payable, CurrentUSD | 19,103,000Source | 13,481,000Source | 23,154,000Source | 13,893,000Source | 32,057,000Source | 13,522,000Source | 14,451,000Source | 9,210,000Source | 28,630,000Source | 12,947,000Source | 15,120,000Source | 15,413,000Source |
| Operating Lease, Liability, NoncurrentUSD | 42,174,000Source | 46,623,000Source | 52,454,000Source | 43,383,000Source | 47,007,000Source | 50,976,000Source | 44,196,000Source | 47,831,000Source | 40,962,000Source | 45,078,000Source | 48,877,000Source | 51,578,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | 0Source | — | — | 0Source | — | — | — | — | — | 4,939,000Source |
| Other Liabilities, NoncurrentUSD | 5,298,000Source | 13,477,000Source | 8,962,000Source | 8,647,000Source | 12,949,000Source | 9,045,000Source | 8,487,000Source | 12,771,000Source | 4,179,000Source | 7,097,000Source | 13,282,000Source | 8,939,000Source |
| Additional Financial Items | ||||||||||||
| AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD | -53,000Source | -188,000Source | -195,000Source | -129,000Source | -197,000Source | -177,000Source | -135,000Source | -203,000Source | -11,000Source | -207,000Source | -188,000Source | -116,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 4,939,000Source |
| Long-term DebtUSD | 391,985,000Source | 389,494,000Source | 394,071,000Source | 391,322,000Source | 388,939,000Source | 393,350,000Source | 390,708,000Source | 388,391,000Source | 392,660,000Source | 390,111,000Source | 387,858,000Source | 391,990,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -21,686,000Source | -48,419,000Source | -27,110,000Source | -56,106,000Source | -151,584,000Source | -236,568,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 1,874,000Source | 2,170,000Source | 1,852,000Source | 2,182,000Source | 1,837,000Source | 2,154,000Source | 7,460,000Source | 8,547,000Source | 7,873,000Source | 5,342,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 25,172,000Source | 30,803,000Source | 87,410,000Source | 84,905,000Source | 86,077,000Source | 76,512,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -15,330,000Source | -9,557,000Source | 5,860,000Source | 19,484,000Source | 20,108,000Source | 17,330,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 8,288,000Source | 1,678,000Source | 111,483,000Source | 73,652,000Source | 44,614,000Source | 5,343,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | -4,939,000Source | 9,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 7,758,000Source | -29,695,000Source | 33,145,000Source | -33,891,000Source | -69,091,000Source | -166,575,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -32,861,000Source | 7,537,000Source | -46,432,000Source | -560,000Source | 98,064,000Source | 92,316,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 212,000Source | 1,811,000Source | 3,296,000Source | 3,553,000Source | 7,440,000Source | 3,766,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 11,790,000Source | 16,721,000Source | 18,323,000Source | 22,025,000Source | 17,920,000Source | 11,490,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -11,700,000Source | -13,309,000Source | 610,000Source | 5,121,000Source | 61,677,000Source | -7,463,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 408,043,000Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -31,984,000Source | -37,283,000Source | 600,000Source | -33,361,000Source | 96,962,000Source | -96,341,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 193,857,000Source | 236,820,000Source | 162,015,000Source | 212,357,000Source | 184,732,000Source | 212,794,000Source | 217,316,000Source | 216,716,000Source | 250,077,000Source | 153,115,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 10,852,000Source | 11,801,000Source | 43,608,000Source | 58,960,000Source | 36,090,000Source | 34,358,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 377,000Source | 635,000Source | 14,894,000Source | 8,214,000Source | 8,525,000Source | 1,609,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 4,819,000Source | -1,816,000Source | 13,277,000Source | -4,031,000Source | 6,312,000Source | -14,619,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 18,089,000Source | 18,688,000Source | 17,559,000Source | 16,197,000Source | 25,172,000Source | 30,803,000Source | 87,410,000Source | 84,905,000Source | 86,077,000Source | 76,512,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 606,000Source | 531,000Source | 2,570,000Source | 2,262,000Source | 2,616,000Source | 2,634,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 3,300,000Source | 3,300,000Source | 2,500,000Source | — |
| Debt Securities, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 3,900,000Source | 5,000,000Source | 4,800,000Source | 4,800,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | -13,933,000Source | 0Source |
| GoodwillUSD | — | — | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source | 197,797,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 16,968,000Source | 13,514,000Source | 5,239,000Source | 15,805,000Source | 3,641,000Source | 4,836,000Source | 27,301,000Source | 27,350,000Source | 1,483,000Source | -5,471,000Source |
| InterestExpenseNonoperatingUSD | — | — | 11,711,000Source | 12,692,000Source | 11,565,000Source | 12,512,000Source | 11,455,000Source | 12,436,000Source | 46,159,000Source | 49,598,000Source | — | — |
| Investment Income, InterestUSD | — | — | 829,000Source | 1,081,000Source | 843,000Source | 1,370,000Source | 812,000Source | 1,540,000Source | 3,317,000Source | 5,407,000Source | 7,078,000Source | 3,024,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 17,306,000Source | -6,729,000Source | -24,420,000Source | -15,697,000Source | -21,686,000Source | -48,419,000Source | -27,110,000Source | -56,106,000Source | -151,584,000Source | -236,568,000Source |
| Operating ExpensesUSD | — | — | 115,325,000Source | 106,579,000Source | 148,945,000Source | 100,441,000Source | 121,503,000Source | 124,557,000Source | 528,492,000Source | 450,476,000Source | 439,241,000Source | 502,754,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 9,500,000Source | 9,800,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 10,887,000Source | -3,263,000Source | 1,015,000Source | -3,717,000Source | 550,000Source | -4,966,000Source | 10,244,000Source | -9,441,000Source | -15,886,000Source | 4,176,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 105,000Source | 3,454,000Source | 19,205,000Source | 7,677,000Source | 10,261,000Source | 4,310,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 169,061,000Source | 141,517,000Source | 154,688,000Source | 126,669,000Source | 125,249,000Source | 110,403,000Source | 634,210,000Source | 528,295,000Source | 399,356,000Source | 329,233,000Source |
| Cost of RevenueUSD | — | — | 19,467,000Source | 13,279,000Source | 15,217,000Source | 11,261,000Source | 11,698,000Source | 13,567,000Source | 72,929,000Source | 52,943,000Source | 37,326,000Source | 38,599,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 90,036,000Source | 75,106,000Source | 84,543,000Source | 73,576,000Source | 91,827,000Source | 88,029,000Source | 383,487,000Source | 323,379,000Source | 275,270,000Source | 213,041,000Source |
| Operating Income (Loss)USD | — | — | 34,269,000Source | 21,659,000Source | -9,474,000Source | 14,967,000Source | -7,952,000Source | -27,721,000Source | 32,789,000Source | 24,876,000Source | -77,211,000Source | -212,120,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 10,887,000Source | -3,263,000Source | 1,015,000Source | -3,717,000Source | 550,000Source | -4,966,000Source | 10,244,000Source | -9,441,000Source | -15,886,000Source | 4,176,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 34,274,000Source | 6,785,000Source | -19,181,000Source | 108,000Source | -18,045,000Source | -43,583,000Source | 191,000Source | -28,756,000Source | -150,101,000Source | -242,039,000Source |
| Income Tax Expense (Benefit)USD | — | — | 16,968,000Source | 13,514,000Source | 5,239,000Source | 15,805,000Source | 3,641,000Source | 4,836,000Source | 27,301,000Source | 27,350,000Source | 1,483,000Source | -5,471,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 17,306,000Source | -6,729,000Source | -24,420,000Source | -15,697,000Source | -21,686,000Source | -48,419,000Source | -27,110,000Source | -56,106,000Source | -151,584,000Source | -236,568,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.06Source | -0.02Source | -0.08Source | -0.05Source | -0.07Source | -0.16Source | -0.09Source | -0.18Source | -0.51Source | -0.82Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.06Source | -0.02Source | -0.08Source | -0.05Source | -0.07Source | -0.16Source | -0.09Source | -0.18Source | -0.51Source | -0.82Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 308,468,423Source | 304,690,596Source | 308,254,256Source | 303,773,922Source | 307,689,207Source | 302,903,009Source | 308,363,768Source | 304,380,502Source | 295,164,515Source | 289,057,198Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 310,433,494Source | 304,690,596Source | 308,254,256Source | 303,773,922Source | 307,689,207Source | 302,903,009Source | 308,363,768Source | 304,380,502Source | 295,164,515Source | 289,057,198Source |
| Interest Expense (non-operating)USD | — | — | 11,711,000Source | 12,692,000Source | 11,565,000Source | 12,512,000Source | 11,455,000Source | 12,436,000Source | 46,159,000Source | 49,598,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 3,300,000Source | 3,300,000Source | 2,500,000Source | — |
| Debt Securities, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | — | — | 149,594,000Source | 128,238,000Source | 139,471,000Source | 115,408,000Source | 113,551,000Source | 96,836,000Source | 561,281,000Source | 475,352,000Source | 362,030,000Source | 290,634,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -123,182,000Source | -210,049,000Source | -234,482,000Source | -343,424,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | 12,436,000Source | — | — | 50,149,000Source | 37,119,000Source |
| Investment Income, InterestUSD | — | — | 829,000Source | 1,081,000Source | 843,000Source | 1,370,000Source | 812,000Source | 1,540,000Source | 3,317,000Source | 5,407,000Source | 7,078,000Source | 3,024,000Source |
| Operating ExpensesUSD | — | — | 115,325,000Source | 106,579,000Source | 148,945,000Source | 100,441,000Source | 121,503,000Source | 124,557,000Source | 528,492,000Source | 450,476,000Source | 439,241,000Source | 502,754,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 9,500,000Source | 9,800,000Source |
Offerings
Registration 333-158405
Registration 333-171648
Registration 333-184531
Registration 333-185307
Registration 333-192747
Registration 333-192876
Registration 333-202474
Registration 333-252566
Filing attachments
tm266897d1_ex99-1.htm · 8-K · 2026-02-20
EX-99.1 2 tm266897d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates 2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, NJ, Feb. 20, 2026 - Amicus Therapeutics (Nasdaq: FOLD), a leading, global biotechnology company with a clear and compelling mission to dev…
Read attachment ↗ny20062454x1_ex107.htm · PREM14A · 2026-01-21
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Amicus Therapeutics, Inc. ( Exact Name of Registrant as Specified in its Charter ) Table 1 - Transaction Valuation Proposed Maximum Fee Rate Amount of Filing Fee Aggregate Value of Transaction ───────────────────────────────────────────────────────────────…
Read attachment ↗ef20061157_ex99-1.htm · 8-K · 2025-12-19
EX-99.1 4 ef20061157_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BioMarin Contacts Amicus Contacts Traci McCarty, Investors Andrew Faughnan, Investors BioMarin Pharmaceutical Inc. Amicus Therapeutics (415) 455-7558 (609) 662-3809 Marni Kottle, Media Brendan McEvoy, Media BioMarin Pharmaceutical Inc. Amicus Therapeutics (415) 218-7111 (202) 320-7767 BioMarin to Acquire Amicus Therapeutics for $4.8 …
Read attachment ↗ef20061157_ex99-2.htm · 8-K · 2025-12-19
EX-99.2 5 ef20061157_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Amicus Employee Letter Subject: Our New Chapter From: Bradley Campbell To: All Employees Team Amicus, Today, we are announcing that Amicus has entered into an agreement to be acquired by BioMarin, a global biotechnology leader in rare genetic diseases, for $14.50 per share in cash, reflecting a total equity value of approximately $4.8 billion. The transaction was unanimously approved by our Board. You can read the press release …
Read attachment ↗tm2530124d1_ex99-1.htm · 8-K · 2025-11-04
EX-99.1 2 tm2530124d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, NJ, Nov. 4, 2025 - Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializi…
Read attachment ↗tm2530124d1_ex99-2.htm · 8-K · 2025-11-04
EX-99.2 3 tm2530124d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Q3 2025 Results Conference Call & Webcast November 4, 2025 ─────────────────────────────── 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the prospects and timing of the potential regulatory and pricing approval of our products, commercializ…
Read attachment ↗